WP4 - Patient-centric market readiness and sustainability

Paving the way for broad, lasting adoption of Point-of-Care CAR-T therapy

WP4 defines and validates patient eligibility criteria to identify new cohorts who stand to benefit from the modular CAR-T device, leveraging clinical expertise and data analytics to model anticipated outcomes. A comprehensive market and competitor analysis maps current trends, barriers to entry, and growth projections, informing optimal positioning within healthcare systems. Finally, insights from WP2 are used for exploitation and sustainability strategies that outline clear commercialization pathways, partner engagement, and scalable roll-out plans to ensure long-term integration and impact of the innovation.

Led by
Fresenius SE & Co. KGaA
and:
Fresenius logo
Charles River logo
Fraunhofer IZI logo
Fresenius Kabi logo
Helmholtz-Zentrum Dresden-Rossendorf logo
quironsalud logo
TQ Therapeutics logo
University Of Glasgow logo
Bar Ilan University logo
Cellix logo
Danmarks Tekniske Universitet logo
Fraunhofer IESE logo
Helios Klinikum Berlin-Buch logo
Philips Electronics Nederland logo
PRO-LIANCE GLOBAL SOLUTIONS logo
See all work packages